Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MIST
- Price
- 1.70
- Stock movement up
- +- (0.00%)
- Company name
- Milestone Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 144.79M
- Ent value
- 165.35M
- Price/Sales
- 1340.63
- Price/Book
- 7.06
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -28.21%
- 1 year return (CAGR)
- -25.76%
- 3 year return (CAGR)
- -23.38%
- 5 year return (CAGR)
- -27.49%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MIST does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1340.63 |
| Price to Book | 7.06 |
| EV to Sales | 1531.04 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 85.17M |
| EPS (TTM) | -0.87 |
| FCF per share (TTM) | -0.65 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 108.00K |
| Gross profit (TTM) | -647.00K |
| Operating income (TTM) | -57.37M |
| Net income (TTM) | -58.01M |
| EPS (TTM) | -0.87 |
| EPS (1y forward) | -0.60 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -599.07% |
| Operating margin (TTM) | -53119.44% |
| Profit margin (TTM) | -53714.81% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 46.69M |
| Net receivables | 1.51M |
| Total current assets | 86.67M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.08M |
| Total assets | 87.75M |
| Accounts payable | 3.18M |
| Short/Current long term debt | 57.21M |
| Total current liabilities | 10.52M |
| Total liabilities | 67.25M |
| Shareholder's equity | 20.50M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -43.18M |
| Capital expenditures (TTM) | 40.98K |
| Free cash flow (TTM) | -43.22M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -282.97% |
| Return on Assets | -66.11% |
| Return on Invested Capital | -75.15% |
| Cash Return on Invested Capital | -55.99% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.70 |
| Daily high | 1.72 |
| Daily low | 1.66 |
| Daily Volume | 1.23M |
| All-time high | 27.15 |
| 1y analyst estimate | 6.60 |
| Beta | 0.46 |
| EPS (TTM) | -0.87 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 31 Mar 2026 |
Downside potential
Loading...
Downside potential data
| MIST | S&P500 | |
| Current price drop from All-time high | -93.74% | -1.82% |
| Highest price drop | -97.60% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -77.54% | -10.84% |
| Avg time to new high | 122 days | 12 days |
| Max time to new high | 1668 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
144.79M
Marketcap category
Small-cap
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Employees
33
Investor relations
-
SEC filings
CEO
Joseph G. Oliveto
Country
USA
City
Montréal
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page